Deep Tech VC reaches billion dollar milestone
Main Sequence surpasses $1 billion funds under management for deep tech as it launches new Fund
Reaching $1B under management in just six years, deep tech backers of Samsara, Regrow, and Q-CTRL tackle decarbonisation and critical technologies with latest $450M fund.
AUSTRALIA, 26 JULY 2023 — Main Sequence, the Australian deep tech investment fund founded by Australia’s national science agency CSIRO, has today announced the first close of its third fund, raising $AU450 million, surpassing the milestone of $AU1 billion in total funds under management.
Recognising that Australia’s expansive research and innovation capabilities offer a unique opportunity to solve global challenges, the fund welcomed the participation of large institutional funds, wealth groups and top tier climate investors. These include high profile new investors as well as many returning investors, underlining their confidence in the fund. Investors include Hostplus, LGT Crestone, Morgan Stanley Wealth Management, Temasek*, NGS Super, Australian Ethical Investment, Daiwa Securities Group and The Grantham Foundation.
The fund also includes the first half of the committed $AU150 million CSIRO investment announced as stage three of the federal government’s Australia’s Economic Accelerator program. It comes as Main Sequence backs and builds companies that reflect Australia’s national priorities investing in ideas that will diversify and transform Australia’s industry and economy.
Founded in 2017, the firm has backed 53 companies including Regrow, Advanced Navigation, and Q-CTRL. The Australian deep tech companies supported by Main Sequence have created over 2,100 new jobs, and the market value of those companies has grown to over $AU6.8 billion.
“Our focus remains on big, global challenges that need scientific backing, patient capital and long-term vision to solve. The community we have created around this mission cares deeply about finding and scaling solutions to planetary problems like decarbonisation, feeding a growing population and enabling the next intelligence leap. Thanks to their support, we have the flexibility and fortitude to back and build breakthrough companies grounded in research, and help them actualise their impact for decades to come.”
This is the third fund from Main Sequence, following its $AU240 million original fund and $AU330 million second fund which closed in 2018 and 2021 respectively.
Main Sequence is not only seeking out these companies, it is finding novel research and building them from scratch through its unique ‘Venture Science’ model of investment. The approach pairs deep scientific knowledge with the industry expertise and capital funding required to build entire industries and ecosystems around solving a global-scale challenge.
“Our last fund saw the launch of five Venture Science startups— Endua, Eden Brew, Quasar Sat, Cauldron, and Samsara Eco. We are keeping up this momentum with Fund 3, pioneering new frontiers in biotechnology and plan to continue co-founding new companies at the bleeding edge of exciting advances in food and fibres with Fund 3,” said Gabrielle Munzer, Partner at Main Sequence.
“We are continuing to harness the forces of entrepreneurship and research to address the ‘Valley of Death’. We see incredible promise in pre-seed investments and our involvement with Australia’s Economic Accelerator, CSIRO’s ON Accelerator and University accelerator programs like UNSW Founders’ SynBio 10x program means we can deepen our focus on unearthing cutting-edge ideas.”